Kura Oncology, Inc. (KURA) — Financial statements
Income statement, balance sheet, and cash flow for Kura Oncology, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 67↑25.2% | 54 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.06 | 0.00↓100.0% | 0.85 | 0.00 | 0.00 | |
| Gross Profit | 67↑25.1% | 54↑6446.6% | -0.85 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 251↑47.7% | 170↑47.5% | 115↑24.2% | 93↑9.6% | 85 | |
| General & Administrative Expenses | 120↑55.6% | 77↑52.5% | 51↑7.5% | 47↑1.1% | 47 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 120↑55.6% | 77↑52.5% | 51↑7.5% | 47↑1.1% | 47 | |
| Other Expenses | 0.00 | 0.00↑100.0% | -0.85 | 0.00 | 0.00 | |
| Operating Expenses | 371↑50.2% | 247↑49.8% | 165↑17.9% | 140↑6.6% | 131 | |
| Total Costs & Expenses | 371↑50.2% | 247↑49.0% | 166↑18.5% | 140↑6.6% | 131 | |
| Operating Results | ||||||
| Operating Income | -304↓57.2% | -193↓16.5% | -166↓18.5% | -140↓6.6% | -131 | |
| Depreciation & Amortization | 1↑21.7% | 0.85↓0.1% | 0.85↑11.9% | 0.76↑36.0% | 0.56 | |
| EBITDA | -276↓62.7% | -169↓12.8% | -150↓11.4% | -135↓4.1% | -129 | |
| EBIT | -277↓62.5% | -170↓12.8% | -151↓11.4% | -136↓4.3% | -130 | |
| Interest & Other Income | ||||||
| Net Interest Income | 25↑19.0% | 21↑61.2% | 13↑227.3% | 4↑408.2% | 0.79 | |
| Interest Income | 27↑17.2% | 23↑55.2% | 15↑246.1% | 4↑252.7% | 1 | |
| Interest Expense | 2↓6.6% | 2↑4.5% | 2↑576.4% | 0.23↓44.7% | 0.41 | |
| Non-Operating Income | -27↓17.2% | -23↓55.2% | -15↓246.1% | -4↓252.7% | -1 | |
| Other Income / Expenses | 25↑19.0% | 21↑61.2% | 13↑227.3% | 4↑408.2% | 0.79 | |
| Income Before Tax | -278↓61.9% | -172↓12.7% | -153↓12.4% | -136↓4.1% | -130 | |
| Income Tax Expense | 0.30↓85.3% | 2 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -279↓60.2% | -174↓14.0% | -153↓12.4% | -136↓4.1% | -130 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -279↓60.2% | -174↓14.0% | -153↓12.4% | -136↓4.1% | -130 | |
| Bottom-Line Net Income | -279↓60.2% | -174↓14.0% | -153↓12.4% | -136↓4.1% | -130 | |
| EPS (Basic) | -3.18↓57.4% | -2.02↑2.9% | -2.08↓2.5% | -2.03↓3.0% | -1.97 | |
| EPS (Diluted) | -3.18↓57.4% | -2.02↑2.9% | -2.08↓2.5% | -2.03↓3.0% | -1.97 | |
| Weighted Average Shares | 88↑1.8% | 86↑17.7% | 73↑9.3% | 67↑1.0% | 66 | |
| Weighted Average Diluted Shares | 88↑1.8% | 86↑17.7% | 73↑9.3% | 67↑1.0% | 66 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.